CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Charles River Laboratories International Inc (CRL) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows mixed signals with no strong upward momentum or clear catalysts to drive significant growth in the near term. While the company has shown some improvement in financial metrics like net income and EPS, the overall revenue decline and bearish technical indicators suggest caution. Analysts have lowered price targets recently, reflecting concerns about slower growth and industry challenges. For a long-term investor, it may be better to wait for stronger positive signals or a more attractive entry point.
The MACD is positive and expanding, indicating some bullish momentum, but the RSI is neutral at 61.738, showing no clear signal. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near a resistance level (R1: 165.502). The stock has a 60% chance to decline slightly in the next day and week, with a modest chance of recovery in the next month (+3.27%).
The CNBC Cures platform and related events have increased public awareness of rare diseases, which could indirectly benefit Charles River Laboratories as a player in the life sciences sector. Improved net income and EPS in the latest quarter also show some financial recovery.
Revenue declined by 0.83% YoY in Q4 2025, and analysts have lowered price targets due to concerns about slower organic growth, lower free cash flow, and industry challenges related to AI. Technical indicators are bearish, and there are no significant insider or hedge fund trading trends to suggest confidence in the stock.
In Q4 2025, revenue dropped by 0.83% YoY to $994.23 million. However, net income improved by 28.21% YoY to -$276.56 million, and EPS increased by 33.18% YoY to -5.62. Gross margin also improved by 11.49% to 30.96%. While some metrics show improvement, the overall revenue decline is a concern.
Analysts have recently lowered price targets, with the majority maintaining Neutral or Outperform ratings. UBS and Mizuho have reduced their targets to $175, citing slower growth and industry concerns, while TD Cowen and others remain optimistic but have also lowered their targets. The consensus reflects mixed sentiment with no strong bullish outlook.
